Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

UltraSound Guided Distal Radial Artery vS Conventional Transradial Access for Interventional Coronary Angiography (US-DRASTIC)

24 de mayo de 2026 actualizado por: Grigorios Tsigkas, University Hospital of Patras
Comparative study of ultrasound-guided distal radial access versus conventional radial access regarding the incidence of vascular access crossover.

Descripción general del estudio

Descripción detallada

Current European and American guidelines issued by the European Society of Cardiology (ESC), the American Heart Association (AHA), and the Society for Cardiovascular Angiography and Interventions (SCAI) recommend transradial access (TRA) as the preferred access route for cardiac catheterization in both acute and chronic coronary syndromes, as well as in complex coronary interventions. Compared with transfemoral access, transradial access has demonstrated significant benefits regarding vascular complications, major bleeding, mortality, and earlier mobilization and discharge of patients.

In recent years, access through the distal segment of the radial artery in the anatomical snuffbox has emerged as a technique with highly beneficial characteristics comparable to conventional radial access, while also offering additional advantages. The ANGIE study demonstrated that distal radial access was associated with a statistically significant reduction in radial artery occlusion compared with conventional radial puncture. Puncture of the distal radial artery preserves antegrade blood flow in the forearm during hemostatic compression, thereby reducing the risk of arterial occlusion.

Existing literature Although the benefit of distal radial access in preventing radial artery occlusion has now been established, the same does not apply to crossover incidence, namely the need to change to an alternative vascular access site because the intervention cannot be completed through the initially selected access.

Several studies have shown higher crossover rates with distal radial access compared with conventional radial access. In the study by Koutouzis et al., distal radial access failed more often, with a crossover incidence of 30% versus 2% in the conventional radial group. Similar findings were reported in the DAPRAO study, the ANGIE trial, the DISCO RADIAL trial, the CONDITION trial, and observational studies and meta-analyses. Overall, published evidence consistently suggests that distal radial access is associated with a higher likelihood of crossover than conventional radial access when performed without ultrasound guidance.

Aim and originality of the study A common characteristic of all the above studies is that the comparison between the two access techniques was performed using anatomical guidance rather than ultrasound guidance.

As noted in the SCAI recommendations, failure to catheterize the radial artery is the leading cause of transradial procedural failure. The radial artery is relatively small in diameter, may be calcified, or may present anatomical variations that complicate vascular access. Two-dimensional ultrasound may therefore be a valuable tool for pre-procedural planning and real-time guidance.

A large meta-analysis of 12 studies including 2,432 adults undergoing conventional transradial access under ultrasound guidance showed improved first-pass success rates and reduced access failure rates. Similarly, ultrasound-guided distal radial access significantly increased successful intervention rates in the study by Mori et al. Consequently, the purpose of the present study is to demonstrate ultrasound guidance as a technique capable of increasing successful completion rates for both vascular approaches, while establishing distal radial access as a non-inferior alternative to conventional radial access regarding crossover probability.

Methodology The study will be conducted after approval by the Scientific Council and the Ethics and Deontology Committee of the University General Hospital of Patras.

This is a prospective, randomized, single-center, non-inferiority clinical study that will be carried out in the Hemodynamic Laboratory of the Cardiology Department of the University General Hospital of Patras in collaboration with the Radiology Department.

Study population The control group will undergo coronary angiography through conventional transradial access (TRA). The intervention group will undergo coronary angiography through distal radial access (DRA). Radial artery puncture will be performed exclusively under ultrasound guidance. Patients meeting the inclusion criteria and none of the exclusion criteria will be randomized in a 1:1 ratio to DRA or TRA.

Arterial access procedure:

The procedure begins with sterilization of both potential puncture sites regardless of randomization group. Conventional radial artery puncture is performed approximately 2-3 cm proximal to the styloid process. In patients randomized to distal transradial access (dTRA), puncture is performed more distally in the anatomical snuffbox at an angle of 30-80 degrees.

The interventional cardiologist uses the ultrasound probe exclusively, covered with a sterile protective sheath, to identify anatomical landmarks, define a safe puncture site, and avoid injury to adjacent structures. Local lidocaine infiltration is then performed under ultrasound guidance. The intravascular position of the needle is confirmed by ultrasound visualization and continuous blood flow.

After successful puncture of the radial artery, a 6 French sheath is inserted using the Seldinger technique. Subsequently, 50 IU/kg unfractionated heparin is administered (100 IU/kg total dose in case of angioplasty), together with nitroglycerin according to standard practice.

Hemostasis procedure After completion of the procedure, a TR band device is used. Hemostasis is assessed at 0,5 ,1, 2, and 3 hours after placement of the device, and if hemostasis is not achieved within this timeframe, manual compression is applied.

Data collection

For all participants, the following will be recorded:

  • Demographic characteristics, cardiovascular risk factors, medical history, and chronic medication
  • Body weight and body mass index (BMI)
  • Reason for catheterization (STEMI, NSTEMI, unstable angina, stable coronary artery disease, suspected coronary artery disease, or valvular disease)
  • Periprocedural antiplatelet or anticoagulant therapy
  • Laboratory tests: Ht, Hgb, PLT, WBC, Urea, Creatinine
  • Allen test and quality of radial artery pulse
  • Total puncture attempts and total time to achieve vascular access
  • Fluoroscopy duration, total angiography time, and contrast volume
  • Number and type of diagnostic catheters used
  • Type of hemostatic device and duration of hemostasis Primary endpoint Need for vascular access crossover due to failed puncture, failed wire or sheath advancement, or inability to complete the procedure through the initial vascular access. The exact reason for crossover will be recorded.

Secondary endpoints

  • Local hematoma classified according to EASY criteria
  • Arterial spasm severity
  • Sheath placement time
  • Total procedural time
  • Time from puncture initiation until completion of coronary angiography before PCI
  • Time required for diagnostic coronary angiography after sheath placement
  • Time required until PCI completion
  • Total fluoroscopy time
  • Total DAP
  • Air Kerma
  • Hemostasis duration
  • Vascular complications (arterial perforation, pseudoaneurysm, arteriovenous fistula)
  • Distal radial artery occlusion before discharge
  • Bleeding events according to BARC classification

Tipo de estudio

Intervencionista

Inscripción (Estimado)

1400

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Athinagoras Theofilatos
  • Número de teléfono: +30 6946747300
  • Correo electrónico: athinag@gmail.com

Copia de seguridad de contactos de estudio

  • Nombre: Grigorios Tsigas, assistant professor
  • Número de teléfono: +30 6974466662

Ubicaciones de estudio

      • Pátrai, Grecia
        • Reclutamiento
        • University Hospital of Patras
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

  • Indication for Invasive coronary angiography

Exclusion Criteria:

  • STEMI
  • Renal replacement therapy patients
  • Serious dermal or bone deformity of the radiocarpal joint
  • Shock

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Otro
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: ultrasound guided distal radial artery
ultrasound guided distal radial artery acess for coronary angiography
Diagnostic and if indicated percutaneus coronary intervention during coronary angiography
Otros nombres:
  • pci
Comparador activo: ultrasound guided conventional transradial acess
ultrasound guided conventional transradial acess for coronary angiography
Diagnostic and if indicated percutaneus coronary intervention during coronary angiography
Otros nombres:
  • pci

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
crossover
Periodo de tiempo: Periprocedural.Up to 5 mins will be allowed before giving up on designated method to obtain access
Need for a different access to begin the procedure other than the one specified in the patient's arm
Periprocedural.Up to 5 mins will be allowed before giving up on designated method to obtain access

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Arterial vasospasm
Periodo de tiempo: periprocedural
periprocedural
hemostasis
Periodo de tiempo: Will be checked at set intervals of 30-60-90-180 mins post procedure
Time from procedure's end until removal of hemostatic device
Will be checked at set intervals of 30-60-90-180 mins post procedure
Time until pci
Periodo de tiempo: periprocedural
Time from first needle puncture until pci (percutaneous coronary intervention) has been completed (If needed)
periprocedural
radial artery occlusion
Periodo de tiempo: 30 days post procedure
ultrasound evaluation of radial artery patency after end of hemostasis
30 days post procedure
hematoma
Periodo de tiempo: pre discharge , post procedure
using EASY classification
pre discharge , post procedure
Time required for sheath insertion
Periodo de tiempo: periprocedural
Time required from first puncture until sheath is sucessfully introduced into the artery
periprocedural
Total procedure time
Periodo de tiempo: periprocedural
Time from first needle puncture until procedure end (hemostatic device placement signals the end )
periprocedural
Coronary angiography time
Periodo de tiempo: periprocedural
Time from first needle puncture until all 3 coronary arteries have been sufficiently depicted
periprocedural

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

12 de mayo de 2026

Finalización primaria (Estimado)

12 de mayo de 2028

Finalización del estudio (Estimado)

1 de noviembre de 2028

Fechas de registro del estudio

Enviado por primera vez

12 de mayo de 2026

Primero enviado que cumplió con los criterios de control de calidad

24 de mayo de 2026

Publicado por primera vez (Actual)

1 de junio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

1 de junio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

24 de mayo de 2026

Última verificación

1 de mayo de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Descripción del plan IPD

We plan to share data with other researchers only if they're formally requested and cited afterwards

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir